Melatonin protects myocardium from ischemia-reperfusion injury in hypertensive rats: Role of myeloperoxidase activity

Clinical and Experimental Hypertension

Volumn 30, Issue 7, 2008, Pages 673-681

  Sahna, Engin ^a   Deniz, Esra ^a   Bay Karabulut, Aysun ^b   Burma, Oktay ^c  

^a FIRAT UNIVERSITY   (Turkey)

^b INONU UNIVERSITY   (Turkey)

^c GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Heart; Hypertension; Ischemia reperfusion; Melatonin; Myeloperoxidase; NO

Indexed keywords

GLUTATHIONE; MALONALDEHYDE; MELATONIN; MYELOPEROXIDASE; N(G) NITROARGININE METHYL ESTER; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME ACTIVITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HYPERTENSION; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; REPERFUSION INJURY;

ANIMALS; BLOOD PRESSURE; ENZYME INHIBITORS; GLUTATHIONE; HYPERTENSION; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MELATONIN; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PEROXIDASE; RATS; RATS, WISTAR;

EID: 54049124483     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960802251966     Document Type: Article

References (37)

1. Ogita H, Liao J. Endothelial function and oxidative stress. Endothelium. 2004;11:123-132.
2. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance? Hypertension. 2004;44:248-252.
3. Alvarez Y, Pérez-Girón JV, Hernanz R, Briones AM, García-Redondo A, Beltrán A, Alonso MJ, Salaices M. Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats. J Pharmacol Exp Ther. 2007;321:381-388.
4. Tengattini S, Reiter RJ, Tan DX, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: Protective effects of melatonin. J Pineal Res. 2008;44:16-25.
5. Portaluppi F, Boari B, Manfredini R. Oxidative stress in essential hypertension. Curr Pharm Des. 2004;10:1695-1698.
6. Sahna E, Parlakpinar H, Turkoz Y, Acet A. Effects of melatonin on myocardial ischemia-reperfusion-induced infarct size and oxidative stress. Physiol Res. 2005;54:491-495.
7. Sahna E, Olmez E, Acet A. Effects of physiological and pharmacological concentrations of melatonin on ischemia-reperfusion arrhythmias in rats: Can the incidence of sudden cardiac death be reduced? J Pineal Res. 2002;32:194-198.
8. Wattanapitayakul SK, Bauer JA. Oxidative pathways in cardiovascular disease: Roles, mechanisms, and therapeutic implications. Pharmacol Therap. 2001;89:187-206.
9. Bernatova I, Pechanova O, Simko F. Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats. Physiol Res. 1996; 45:311-316.
10. Kanematsu Y, Tsuchiya K, Ohnishi H, Motobayashi Y, Izawa Y, Ishihara M, Ishizawa K, Abe S, Kawazoe K, Tamaki T. Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in Nω-nitro-L-arginine methyl ester-treated rats. Hypertens Res. 2006;29:369-374.
11. Pechanova O, Bernatova I, Babal P, Martinez MC, Kysela S, Stvrtina S, Andriantsitohaina R. Red wine polyphenols prevent cardiovascular alterations in L-NAME-induced hypertension. J Hypertens. 2004;22:1551-1559.
12. Deniz E, Colakoglu N, Sari A, Sonmez MF, Tugrul I, Oktar S, Ilhan S, Sahna E. Melatonin attenuates renal ischemia-reperfusion injury in nitric oxide synthase inhibited rats. Acta Histochem. 2006;108:303-309.
13. Liu P, Xu B, Forman LJ, Carsia R, Hock CE. L-NAME enhances microcirculatory congestion and cardiomyocyte apoptosis during myocardial ischemia-reperfusion in rats. Shock. 2002;17:185-192.
14. Reiter RJ, Tan DX. Melatonin: A novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovascular Res. 2003;58:10-19.
15. Sahna E, Deniz E, Aksulu HE. Myocardial ischemia-reperfusion injury and melatonin. Anadolu Kardiyol Derg. 2006;6:163-168.
16. Sener G, Sehirli AO, Ayanoglu-Dulger G. Melatonin protects against mercury (II)-induced oxidative tissue damage in rats. Pharmacol Toxicol. 2003;93:290-296.
17. Girouard H, Denault C, Chulak C, de Champlain J. Treatment by n-acetylcysteine and melatonin increases cardiac baroreflex and improves antioxidant reserve. Am J Hypertens. 2004;17:947-954.
18. Arangino S, Cagnacci A, Angiolucci M, Vacca AM, Longu G, Volpe A, Melis GB. Effects of melatonin on vascular reactivity, catecholamine levels and blood pressure in healthy men. Am J Cardiol. 1999;83:1417-1419.
19. Pechanova O, Zicha J, Paulis L, et al. The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur J Pharmacol. 2007;561:129-136.
20. Deniz E, Sahna E, Aksulu HE. Nitric oxide synthase inhibition in rats: Melatonin reduces blood pressure and ischemia/reperfusion-induced infarct size. Scandinavian Cardiovascular Journal. 2006;40:248-252.
21. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods. 1985;14:157-167.
22. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by tiobarbituric acid test. Anal Biochem. 1978;34:271-278.
23. Fairbanks V, Klee GG. Biochemical aspects of hematology. In: Tietz NW, ed. Textbook of Clinical Chemistry. Philadelphia: W.B. Saunders, 1986, 1532-1534.
24. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflamation: Estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982;78:206-209.
25. Husain K. Interaction of exercise training and chronic NOS inhibition on blood pressure, heart rate, NO and antioxidants in plasma of rats. Pathophysiology. 2003;10:47-56.
26. Chuang JI, Chen SS, Lin MT. Melatonin decreases brain serotonin release, arterial pressure, and heart rate in rats. Pharmacology. 1993;47:91-97.
27. Girouard H, Chulak C, Lejossec M, Lamontagne D, de Champlain J. Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. J Hypertens. 2001;19:1369-1377.
28. Birau N, Peterssen U, Meyer C, Gottschalk J. Hypotensive effect of melatonin in essential hypertension. IRCS Med Sci. 1981;9:906.
29. Lefer DJ, Granger DN. Oxidative stress and cardiac disease. Am J Med. 2000;109:315-323.
30. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47.
31. Kitakaze M, Node K, Takashima S, Minamino T, Kuzuya T, Hori M. Cellular mechanisms of cardioprotection afforded by inhibitors of angiotensin converting enzyme in ischemic hearts: Role of bradykinin and nitric oxide. Hypertens Res. 2000;23:253-259.
32. Entman ML, Smith CW. Postreperfusion inflammation: A model for reaction to injury in cardiovascular disease. Cardiovasc Res. 1994;9:1301-1311.
33. Lefer J, Jones SP, Girod WG, Baines A, Grisham MB, Cockrell AS, Huang PL, Scalia R. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am J Physiol Heart Circ Physiol. 1999;276:1943-1950.
34. Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in endotoxic shock. Cardiovasc Res. 1992;26:48.
35. Tiefenbacher CP, Kapitza J, Dietz V, Lee CH, Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol. 2003;285:59-64.
36. Baldus S, Heitzer T, Eiserich JP, et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med. 2004;37:902-911.
37. Lefer DJ, Nakanishi K, Johnston WE, Vinten-Johansen J. Antineutrophil and myocardial protecting actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion of dogs. Circulation. 1993;88:2337-2350.